All News

Abstract#0703 Multicenter observational study of RA-ILD pts tx with UPA (n=43). PFTs were stable for 24 month period, HRCT stable or improved in 90%. Remission or LDA by DAS-ESR in 60% of this pop. DMARD to consider when RA-ILD is in play? @ACR26 @RheumNow

Sapkota et al. For hospitalised RA patients. Pulmonary involvement in RA conferred a >3-fold higher adjusted odds of inpatient death and significantly greater hospital cost and LOS @RheumNow #ACR26 Abstr#0498 https://t.co/tRck29gMxQ

https://x.com/RichardPAConway/status/2119484343139885288/photo/1

Erkek et al. Leflunomide in RA-ILD Each additional month of LEF was associated with a 4% lower risk of radiologic worsening (RR per month≈0.96, p< 0.01), and each additional gram of cumulative dose with a 6.4% lower risk (RR per 1 g≈0.94, p< 0.01). @RheumNow #ACR26 Abstr#0495 https://t.co/kepQ1BHfAT

https://x.com/RichardPAConway/status/2119483085171437941/photo/1

Moura et al. (RA GLP-1 cohort): each 10 lb weight loss associated with 0.32-point lower RAPID3. Achieving >=15% weight loss was linked to higher odds of RAPID3 MCID (aOR 1.66). @rheumnow #ACR2026 Abstract#0484 https://t.co/gSDdXmlanH

https://x.com/Gibson_RheumPAC/status/2119482584694481232/photo/1

Moura et al. (RA GLP-1 cohort): More weight loss, better patient-reported RA outcomes? Odds of RAPID3 MCID rose across >=5%, >=10% and >=15% weight-loss groups. @rheumnow #ACR2026 Abstract#0484 https://t.co/Vk9Cf52SIU

https://x.com/Gibson_RheumPAC/status/2119482583717126652/photo/1

Huz et al. 258 RA-ILD patients. HR 2.28, 95%CI 1.18, 4.40 for mortality/lung transplant in mod/high disease activity. Numerical, 2.1 years mod/high disease activity vs 3.7 years but not statistically significant difference in functional progression. @RheumNow #ACR26 Abstr#0490 https://t.co/EMSdQPMLRS

https://x.com/RichardPAConway/status/2119480568480198878/photo/1

Munoz et al. Baricitinib in RA-ILD. 84 patients. FVC and DLCO remained stable through 36 months. Dyspnea and HRCT findings improved or remained stable in 83% and 68% of patients at 48 months. @RheumNow #ACR26 Abstr#0478 https://t.co/yDQCiR6FHN

https://x.com/RichardPAConway/status/2119479813584846964/photo/1

Sullivan et al. RA, particularly those with COPD, had higher risk of acute respiratory exacerbation than those without RA and results were not explained by potential confounders including age, sex, and smoking intensity. @RheumNow #ACR26 Abstr#0477 https://t.co/nciY35ACha

https://x.com/RichardPAConway/status/2119479310226804794/photo/1

Rakholiya et al. Novel anti-Sa antibodies associated with ILD in "seronegative" RA. Anti-Sa seen in 14.7% of seronegative RA. 42.9% anti-Sa+ had ILD, only 2.4% anti-Sa- did @RheumNow #ACR26 Abstr#0475 https://t.co/ZaOrBn7gx9

https://x.com/RichardPAConway/status/2119478303472103681/photo/1

Purohit et al. (Veterans GLP-1 CV cohort): Veterans with rheumatic disease and diabetes: GLP-1 users had lower composite CV events/death vs DPP-4 users (HR 0.86; 95% CI 0.76-0.99). Propensity matched, still observational. @rheumnow #ACR2026 Abstract#1784 https://t.co/Ymfqg8vxDW

https://x.com/Gibson_RheumPAC/status/2119475031877247348/photo/1

Conaghan et al. (TRIUMPH-4): A clinically important TRIUMPH-4 safety detail: gastrointestinal events were the commonest adverse effects, mostly mild-moderate and during dose escalation. Monitor tolerability, not just efficacy. @rheumnow #ACR2026 Abstract#0871 https://t.co/fzD7LulZMQ

https://x.com/Gibson_RheumPAC/status/2119469998846754960/photo/1

Moura et al: In RA/PsA patients starting GLP-1 therapy, each 5% weight reduction was linked to better RAPID3 scores. Pain and patient global improved most. Weight loss may change how we interpret disease activity. @rheumnow #ACR2026 #ACRBest Abstract#0867

If you were ever worried about patient joint count over telehealth in RA, it'd be in pts with fibro in fact: fibro/non-fibro trained pts missed SJC up/down the DAS & CDAI turned out okay a 5min training video worth it, for better telehealth assessment ABST0781 #ACR26 @RheumNow https://t.co/ErPbtuclZ2

Gastric bypass in RA (n=53) lowered CRP and medication use. In the SOS cohort, bariatric surgery lowered psoriasis risk but not RA risk. Weight loss may act differently in PsA and RA. Size Matters session @RheumNow #ACR26

The risk of obesity is higher in pts w/ rheumatic dses Stronger effect of obesity in females with PsA and gout Obesity also incr dse activity in OA, gout, PsA, RA, SpA and SLE Sjogren’s and Scl - not much evidence on assocn w/ obesity & its effect on dse act @RheumNow #ACR26 https://t.co/Nf63plqDZr

Ortiz et al. RA-ILD. Nintedanib added to abatacept stabilises PFTs in progressive pulmonary fibrosis. No apparent benefit in stable disease. @RheumNow #ACR26 Abstr#0448 https://t.co/6OmS3KKiNb

https://x.com/RichardPAConway/status/2119459938049388669/photo/1

Can we eliminate pathogenic T cells while preserving overall T-cell counts? #ACR26 Abst 0868: Rosnilimab depleted >90% of PD-1high pathogenic T cells, downregulating synovial IL-6, TNF & IFN pathways. A new paradigm in RA? @RheumNow https://t.co/AQbDLy0Iox

Older pts still need maintenance! Much higher risk of flare and hospitalization among elderly pts who did not receive RTX for maintenance Those who received RTX ahd lower pred-equivalent exposure (1,825 vs 2,814 w/RTX) There are no solutisn; only trade-offs. Holding RTX for https://t.co/DMNvKXdk3a

What does rosnilimab do in joints of people with RA? Phase 2b biopsies showed ~90% fewer synovial PD-1+ T cells and ~80% fewer B cells at week 6, alongside reduced inflammatory pathways. @Rheumnow #0868 #ACR26 https://t.co/nnRA15YOis

https://x.com/DrMiniDey/status/2119455402668773877/photo/1

Unmet need for immune reset, rheumatologist survey (n=105) Mean rank, 1 = greatest need: SSc 1.8 (68% ranked it 1st) IIM 3.7 LN 3.9 SLE 5.1 D2T RA 6.5, PsA 7.8 Most CAR-T data are in SLE, yet non-renal SLE ties for 5th of 9. Dinesh Khanna @RheumNow #ACR26 https://t.co/EhbxDUFd8q

https://x.com/he67407/status/2119455209906692286/photo/1

Topics

All News

Do you get our email newsletter?